Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$92.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abbott Laboratories Shares Scorched By Kidney Drug Failure-Reuters


Thursday, 18 Oct 2012 12:55pm EDT 

Reuters reported that Abbott Laboratories said its partner, Reata Pharmaceuticals, was discontinuing a late-stage trial of their potential blockbuster treatment for chronic kidney disease and diabetes based on safety concerns raised by an independent safety committee. An independent data-monitoring committee found excess serious adverse events and mortality in patients taking the oral anti-inflammatory drug, Abbott said in a regulatory filing. 

Company Quote

43.4
-0.19 -0.44%
22 Sep 2014